Home  »  Stocks to Invest   »  RedHill Biopharma Ltd. (RDHL) Stock on the Rise Fo...

RedHill Biopharma Ltd. (RDHL) Stock on the Rise Following Positive Topline Results from Opaganib Study

RedHill Biopharma Ltd. (RDHL) stock prices were up by 11.67% as of the market closing on October 4th 2021. This brought the price per share up to USD$4.88 at the end of the trading day. Subsequent premarket fluctuations have seen the stock surge by 4.71%, bringing it up to USD$5.11.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


RDHL Stock’s Study Results

October 4th 2021 saw RDHL stock announce new data from its ongoing opaganib global Phase 2/3 study. The study is designed to treat hospitalized patients with severe Covid-19 pneumonia. It evaluated oral opaganib vs the placebo controlled arm, with the oral treatment exhibiting promising results. The opaganib treatment arm resulted in a 62% statistically significant reduction in mortality. The treatment also exhibited statistically significant improved outcomes in time to room air and median time to hospital discharge. These results were gathered from a cohort of 251 hospitalized patients with moderately severe Covid-19, which comprises 53% of the total 475 study participants.

Details of the Clinical Trial

The important new results were generated from a post-hoc analysis of data from the 251 study participants. These patients required a Fraction of inspired Oxygen (FiO2) up to 60% at baseline. Patients with an FiO2 lower than 61% are considered to be severely affected and typically require oxygen supplementations via a nasal cannula or face mask. The new findings support the treatment’s potential viability in hospitalized, moderately severe Covid-19 patients. This demographic of patients is at high risk of disease progression, morbidity, and mortality. These patients are hoped to benefit from the treatment’s combined antiviral and anti-inflammatory activities.

Building on Success

The promising results serve to provide a strong rationale for the treatment’s potential efficacy in hospitalized patients. These patients demonstrate a need for oxygen supplementation of up to 60% FiO2. The Phase 2/3 study results have also proven to be consistent the treatment’s earlier Phase 2 study results. The treatment also exhibited potent antiviral inhibition of Covid19 variants in human bronchial epithelial cells. With the coronavirus variants popping up across the globe, the treatment serves to further provide support for its potential in earlier stages of disease where the viral load is higher.

Future Outlook for RDHL Stock

The company reported a strong quarter, consolidated by the promising new data generated from the ongoing opaganib clinical trial. RDHL stock is poised to capitalize on the expanded scope of opportunities presented to it in light of its recent developments. Current and potential investors are hopeful that management will be able to leverage the resources at its disposal. This is hoped to facilitate significant and sustained increases in shareholder value over the long term.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam